Advertisement
Advertisement

ARWR

ARWR logo

Arrowhead Research Corporation

60.82
USD
Sponsored
+4.55
+8.08%
Mar 25, 16:00 UTC -4
Closed
exchange

After-Market

60.51

-0.31
-0.51%

ARWR Earnings Reports

Positive Surprise Ratio

ARWR beat 12 of 40 last estimates.

30%

Next Report

Date of Next Report
May 11, 2026
Estimate for Q2 26 (Revenue/ EPS)
$77.20M
/
-$1.21
Implied change from Q1 26 (Revenue/ EPS)
-70.76%
/
-650.00%
Implied change from Q2 25 (Revenue/ EPS)
-85.78%
/
-144.00%

Arrowhead Research Corporation earnings per share and revenue

On Feb 05, 2026, ARWR reported earnings of 0.22 USD per share (EPS) for Q1 26, missing the estimate of 0.25 USD, resulting in a -14.76% surprise. Revenue reached 264.03 million, compared to an expected 275.47 million, with a -4.15% difference. The market reacted with a -0.19% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 13 analysts forecast an EPS of -1.21 USD, with revenue projected to reach 77.20 million USD, implying an decrease of -650.00% EPS, and decrease of -70.76% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Celcuity Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$1.06
Actual
-$0.97
Surprise
+8.72%
logo
Precigen, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.01
Surprise
+88.24%
logo
Absci Corporation Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.19
Actual
-$0.23
Surprise
-16.04%
logo
Candel Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.25
Actual
-$0.54
Surprise
-115.31%
logo
LENZ Therapeutics, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.99
Actual
-$1.15
Surprise
-17.10%
logo
Fennec Pharmaceuticals Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
$0.03
Actual
-$0.11
Surprise
-408.12%
logo
Equillium, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.06
Actual
-$0.04
Surprise
+35.28%
logo
MaxCyte, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.06
Surprise
+26.47%
logo
Dyadic International, Inc.
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.04
Actual
-$0.06
Surprise
-30.72%
logo
TELA Bio, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.16
Surprise
+14.12%
FAQ
For Q1 2026, Arrowhead Research Corporation reported EPS of $0.22, missing estimates by -14.76%, and revenue of $264.03M, -4.15% below expectations.
The stock price moved down -0.19%, changed from $64.64 before the earnings release to $64.52 the day after.
The next earning report is scheduled for May 11, 2026.
Based on 13 analysts, Arrowhead Research Corporation is expected to report EPS of -$1.21 and revenue of $77.20M for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement